From promise to people.

At Lineage, our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions

Our
Pipeline

Company
Presentation

Genentech and Lineage are working together to expand benefits of cell therapy to eye diseases

We’re teaming up to create allogeneic retinal pigment epithelial (RPE) cells to either replace or support cells that are dysfunctional or absent due to degenerative disease

In the Media

View more media

OPC1 Patient Spotlight

Sonia’s OpRegen Story

News and Events

View more news and events

May 11, 2023 – Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 26, 2023 – RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

Recent Financials

Listen to our 1^st Quarter 2023
Earnings Call